Trinity Biotech
TRIB
45 hedge funds and large institutions have $78.4M invested in Trinity Biotech in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 3 closing their positions.
3% more capital invested
Capital invested by funds: $76M → $78.4M (+$2.4M)
0.06% more ownership
Funds ownership: 3.15% → 3.21% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 48 → 45 (-3)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$3.7M |
| 2 |
2L
22NW LP
Seattle,
Washington
|
+$374K |
| 3 |
Renaissance Technologies
New York
|
+$339K |
| 4 |
LAM
Lapides Asset Management
Greenwich,
Connecticut
|
+$210K |
| 5 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$1.22M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$929K |
| 3 |
Millennium Management
New York
|
-$270K |
| 4 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$186K |
| 5 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
-$140K |
TRIB Hedge Fund Activity: Q1 2018 in Review
45 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2018, worth a combined $78.4M — up 3.2% from $76M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TRIB and 1 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Russell Investments Group, adding an estimated $3.7M. The largest seller was Boston Partners, cutting an estimated $1.22M.
- 45 institutional investors held Trinity Biotech (TRIB) as of Q1 2018, down from 48 in Q4 2017.
- Funds reported $78.4M of Trinity Biotech stock for Q1 2018, up 3.2% quarter-over-quarter.
- 1 fund opened new Trinity Biotech positions in Q1 2018 and 3 closed out, a net change of -2 holders.
- The largest Trinity Biotech buyer in Q1 2018 was Russell Investments Group, an estimated $3.7M added.
- The largest Trinity Biotech seller in Q1 2018 was Boston Partners, an estimated $1.22M sold.
Based on aggregated 13F filings for Q1 2018.